

Mangalam Drugs and Organics Ltd.



Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.
Phone : 91-22-22616200 / 6300 / 8787 • Fax : 91-22-22619090 • CIN : L24230MH1972PLC116413

22nd May, 2017

To
BSE Ltd.
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001.

Sub: Audited Financial Results for the Quarter and year ended on 31st March, 2017 in the revised format as per the SEBI Circular No. CIR/CFD/FAC/62/2016 dated 05th July, 2016.

Scrip Code: 532637
Symbol: MANGALAM

Dear Sir,

This is with reference to your email requesting the Company to re-submit the Audited Financial Results for the year ended 31st March, 2017, in the revised format pursuant to SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016.


Please find attached herewith the statement showing the Audited Financial Results for the quarter / year ended 31st March, 2017 along with Statement of Assets and Liabilities and Auditor's Report of the Statutory Auditors of the Company in the revised format, wherein, there are no changes or variations in the figures as compared to the Audited Financial Results submitted by the Company on 08th May, 2017.

The report of Auditors is with unmodified opinion with respect to Audited financial results (Standalone) for the quarter and year ended 31st March, 2017. Declaration to that effect is also enclosed herewith.

Kindly take the same in your records and inform all your constituents accordingly.

Thanking You,
Yours faithfully,
For **Mangalam Drugs & Organics Ltd**

Nikita Bavishi
Nikita Bavishi
Company Secretary.



Audited Financial Results for the Quarter and Year Ended 31st March 2017 approved and taken on record by the Board at their meeting dated 8th May 2017

(Rs. in Lacs)

Sr. No.	Particulars	Audited (Refer Note-3)	Unaudited		Audited	Audited
		Quarter ended			Year ended	Year Ended
		Current Quarter ended	Previous 3 months ended in the current year	Corresponding 3 months ended in the previous year	Current accounting year ended	Previous accounting year ended
		31.3.17	31.12.16	31.3.16	31.03.17	31.03.16
A	PART I - STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31ST MARCH 2017					
1	Revenue from Operations	8760.14	8057.84	7368.32	31263.65	30328.73
2	Other Income	1.19	3.65	0.00	6.37	5.84
3	Total Revenue(1+2)	8761.33	8061.49	7368.32	31270.02	30334.57
4	Expenses					
	(a) Cost of Material Consumed	3799.96	4570.39	4461.42	18190.96	20239.12
	(b) Changes in inventories of finished goods work in progress and stock in trade	1543.18	226.22	(417.77)	1556.91	(7.95)
	(c) Employee Benefits Expenses	473.25	511.15	410.23	1852.28	1438.69
	(d) Finance costs	310.77	228.00	277.03	1003.65	929.18
	(e) Depreciation	154.99	129.89	108.62	500.71	441.30
	(f) Excise duty & service tax recovered	463.93	361.93	302.09	955.83	812.66
	(g) Other Expenses	1065.62	1169.28	1249.96	3871.44	4079.97
	(h) Total Expenses	7811.70	7196.86	6391.58	27931.78	27932.97
	Profit(+)/Loss before exceptional and extraordinary items and tax (3-4)	949.63	864.63	976.74	3338.24	2401.60
6	Exceptional Items	0.00	0.00	0.00	0.00	0.00
7	Profit (+) / Loss before extraordinary items and tax (5-6)	949.63	864.63	976.74	3338.24	2401.60
8	Extraordinary Items	0.00	0.00	0.00	0.00	0.00
9	Profit(+)/Loss before tax (7-8)	949.63	864.63	976.74	3338.24	2401.60
10	Tax Expenses					
	Current tax	244.20	201.00	259.00	798.10	487.75
	Deferred tax	49.35	44.00	356.34	170.45	675.09
	Mat credit entitlement	0.00	0.00	(192.05)	0.00	(364.55)
11	Net Profit(+)/Loss(-) after Tax (9-10)	656.08	619.63	553.45	2369.69	1603.31
12	Paid up Equity Share Capital (face value Rs.10/-each)	1582.82	1582.82	1437.82	1582.82	1437.82
13	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year.	7033.55	0.00	3866.36	7033.55	3866.36
14	Earning per share (EPS) (of Rs.10/- each) not annualised) :					
	(a) Basic	4.14	3.92	3.85	14.97	11.15
	(b) Diluted	4.14	3.92	3.50	14.97	10.13

Notes:

- The above results have been reviewed by the Audit Committee and thereafter, were taken on record by the Board of Directors of the Company at their meeting held on 8th May 2017
- As the Company's business activity falls within a single primary business segment viz "Manufacturing of Bulk drugs" the disclosure requirement of Accounting Standard(AS-17)"Segment Reporting" is not applicable.
- The results for the quarter ended March 31,2017 are derived figures arrived at by subtracting the results for the nine months ended on December 31,2016 from the audited results for the year ended March 31,2017
- Previous year figure are regrouped wherever necessary.

Place: Mumbai
Date: 08.05.2017

On behalf of Board of Directors
For Mangalam Drugs & Organics Ltd

(Shri Govardhan M.Dhoot)
Chairman & Managing Director
DIN:01240086



STATEMENT OF ASSETS & LIABILITIES



(Rs.In Lacs)

Particulars		As at 31 March, 2017	As at 31 March, 2016
A	EQUITY AND LIABILITIES		
1	Shareholders' funds		
	(a) Share capital	1,582.82	1,437.82
	(b) Reserves and surplus	7,033.55	3,866.36
	(c) Money recd twds Share Warrants	-	848.25
	Sub Total -Shareholders Funds	8,616.37	6,152.43
2	Non-current liabilities		
	(a) Long-term borrowings	2,073.56	1,692.15
	(b) Deferred Tax Liabilities (Net)	1,015.34	844.89
	Sub Total -Non-Current Liabilities	3,088.90	2,537.04
3	Current liabilities		
	(a) Short-term borrowings	3,754.50	3,537.57
	(b) Trade payables	2,077.55	2,067.50
	(c) Other current liabilities	1,566.41	1,681.85
	Sub Total -Current Liabilities	7,398.46	7,286.92
	TOTAL	19,103.73	15,976.39
B	ASSETS		
1	I) Non-current assets		
	(a) Fixed Assets(Tangible Assets)	9255.62	5911.70
	(b) Long-term loans and advances	116.27	99.31
	Sub Total -Non-Current Assets	9,371.89	6,011.01
2	Current assets		
	(a) Current Investments	24.39	24.01
	(b) Inventories	3,724.95	4,734.06
	(c) Trade receivables	3,975.07	3,014.43
	(d) Cash and cash equivalents	62.73	49.53
	(e) Short-term loans and advances	1,944.70	2,143.35
	Sub Total -Current Assets	9,731.84	9,965.38
	TOTAL	19,103.73	15,976.39


Notes: 1) Previous periods/years figures have been regrouped/rearranged wherever necessary.

On behalf of Board of Directors
For Mangalam Drugs & Organics Ltd

(Shri Govardhan M.Dhoot)
Chairman & Managing Director
(DIN:01240086)

Place: Mumbai
Date: 08.05.2017





18, Bagaria House, 1st Floor, 31/33, Dr. M.B. Velkar Lane, Mumbai - 400 002.
Tel : 22036132 / 9821162679 E-mail: rakesh_milwani@hotmail.com

**Auditor's Report On Quarterly Financial Results and Year to Date Results of the
Company Pursuant to the Regulation 33 of the SEBI
(Listing Obligations and Disclosure Requirement) Regulations, 2015**

To
Board of Directors
Mangalam Drugs & Organics Ltd.,
Mumbai

We have audited the quarterly financial results of Mangalam Drugs & Organics Ltd., for the quarter ended 31st March 2017, and the year to date results for the period 1st April 2016 to 31st March 2017, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015. These quarterly financial results as well as the year to date financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting (AS 25/ Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder; as applicable and other accounting principles generally accepted in India.

We conducted our audit in accordance with the auditing standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(s). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.



Contd....2/-




18, Bagaria House, 1st Floor, 31/33, Dr. M.B. Velkar Lane, Mumbai - 400 002.
Tel. : 22036132 / 9821162679 E-mail: rakesh_milwani@hotmail.com

: 2 :

In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

(i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015 in this regard; and

(ii) give a true and fair view of the net profit and other financial information for the quarter ended 31st March 2017, as well as the year to date results for the period from 1st April 2016 to 31st March 2017.



For MILWANI ASSOCIATES
Chartered Accountants
F.R.N.:106405W

(CA Rakesh K. Milwani) Proprietor
Membership No.: 036099

(CA RAKESH K. MILWANI)

Proprietor: MILWANI ASSOCIATES

CHARTERED ACCOUNTANTS

Membership No.036099

Firm Registration No. 106405W

Place : Mumbai

Date : 8th May, 2017.

Mangalam Drugs and Organics Ltd.

Regd. Office : Rupam Building, 3rd Floor, 239 P. D'Mello Road, Near G. P. O. Mumbai - 400 001.
Phone : 91-22-22616200 / 6300 / 8787 • Fax : 91-22-22619090 • CIN : L24230MH1972PLC116413



08th May, 2017

To,

BSE Limited
P. J. Towers,
Dalal Street,
Mumbai – 400 001.

National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
BandraKurla Complex,
Bandra (E), Mumbai – 400 051

Scrip Code: 532637

Symbol: MANGALAM

Sub: Declaration pursuant to Regulation 33(3)(d) of SEBI (Listing Obligation and Disclosure Requirements), Regulations, 2015

Dear Sir/Madam,

This is to declare that the Statutory Auditors of the Company i.e. Milwani Associates, Chartered Accountants (Firm Registration No. 106405W) have issued an Audit Report with unmodified opinions on Standalone Annual Audited Financial Results for the Year ended 31st March, 2017. Hence, provisions of "Statement on Impact of Audit Qualifications" are not applicable to the Company.

This declaration is issued in compliance with Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements)(Amendment) Regulations, 2016, as issued by the Securities and Exchange Board of India vide Notification No. SEBI/LAD-NRO/GN/2016-17/001 dated May 25, 2016.

Thanking you,

Yours faithfully,

For MANGALAM DRUGS & ORGANICS LTD.


Govardhan M. Dhoot
Managing Director
DIN: 01240086

